Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Acadia Pharmaceuticals Inc’s stock clocked out at $21.85, up 0.74% from its previous closing price of $21.69. In other words, the price has increased by $0.74 from its previous closing price. On the day, 2.62 million shares were traded.
Ratios:
To gain a deeper understanding of ACAD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.64. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.
Guggenheim Downgraded its Buy to Neutral on January 03, 2025, whereas the target price for the stock was revised from $23 to $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 16 ’25 when Kihara James sold 4,000 shares for $22.50 per share. The transaction valued at 90,000 led to the insider holds 20,395 shares of the business.
Schneyer Mark C. sold 2,000 shares of ACAD for $50,000 on May 16 ’25. The EVP, CHIEF FINANCIAL OFFICER now owns 62,130 shares after completing the transaction at $25.00 per share. On May 16 ’25, another insider, Schneyer Mark C., who serves as the Officer of the company, bought 2,000 shares for $17.60 each.
Valuation Measures:
As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.91, and their Forward P/E ratio for the next fiscal year is 25.50. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.67 while its Price-to-Book (P/B) ratio in mrq is 4.77.
Stock Price History:
Over the past 52 weeks, ACAD has reached a high of $25.23, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is 33.69%, while the 200-Day Moving Average is calculated to be 30.77%.
Shares Statistics:
A total of 167.12M shares are outstanding, with a floating share count of 166.05M. Insiders hold about 0.78% of the company’s shares, while institutions hold 103.80% stake in the company.
Earnings Estimates
The stock of Acadia Pharmaceuticals Inc (ACAD) is currently drawing attention from 14.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.14, with high estimates of $0.2 and low estimates of $0.06.
Analysts are recommending an EPS of between $1.0 and $0.35 for the fiscal current year, implying an average EPS of $0.54. EPS for the following year is $0.89, with 15.0 analysts recommending between $1.86 and $0.5.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $263.07M. It ranges from a high estimate of $274.23M to a low estimate of $255.9M. As of the current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $241.96MFor the next quarter, 18 analysts are estimating revenue of $274.62M. There is a high estimate of $291.5M for the next quarter, whereas the lowest estimate is $269M.
A total of 20 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.05B, resulting in an average revenue estimate of $1.06B. In the same quarter a year ago, actual revenue was $957.8MBased on 20 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.33B and the low estimate is $1.12B.
